Clinical efficacy and safety of single course CCR regimen in treatment of hairy cell leukemia: report of 4 cases
10.3760/cma.j.cn115356-20231225-00117
- VernacularTitle:单疗程CCR方案治疗毛细胞白血病4例临床效果及安全性
- Author:
Ling GAO
1
;
Yi MIAO
;
Wenyu SHI
;
Jianyong LI
;
Huayuan ZHU
Author Information
1. 南京医科大学第一附属医院 江苏省人民医院血液科，南京 210029
- Keywords:
Leukemia, hairy cell;
Antineoplastic combined chemotherapy protocols;
Cyclophosphamide;
Claritrobin;
Rituximab;
Treatment outcome;
Adverse reactions
- From:
Journal of Leukemia & Lymphoma
2024;33(7):416-420
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the clinical efficacy and safety of CCR (cyclophosphamide+clarithrobin+rituximab) regimen in the treatment of hairy cell leukemia (HCL).Methods:A retrospective case series study was performed. The clinical data of 4 HCL patients who received the treatment of single course CCR regimen in the First Affiliated Hospital of Nanjing Medical University from October 2015 to March 2023 were collected. The short-term efficacy and safety of CCR regimen were summarized, and the survival status of patients was evaluated by using Kaplan-Meier method.Results:All 4 patients were initial-treated classic HCL, including 3 males and 1 female, with a median age of 46 years old (range: 41-66 years old). The median follow-up time of 4 patients was 34.5 months (range: 4-92 months). Four months after the end of treatment, 3 patients achieved complete remission (CR), and 1 patient achieved partial remission (PR); none of 3 CR patients had minimal residual disease. The prognostication of Kaplan-Meier method showed that all 4 patients had progression-free survival and overall survival at 5 years. No serious drug-related adverse events occurred during the treatment process. No infusion response related to rituximab occurred. Two patients developed grade 1 fatigue, 1 patient developed grade 2 pneumonia; 1 patient developed grade 4 granulocytopenia, 3 patients developed grade 4 thrombocytopenia, and no bleeding event occurred; all adverse reactions were controllable.Conclusions:The single course CCR regimen has good efficacy and safety in treating HCL, and it can serve as a new attempt in clinical treatment of HCL.
